IP Library Granted Patent US 8,481,590
Granted Patent B2
US 8,481,590 · App. 13/521,820 · Granted Jul 9, 2013

Chromone inhibitors of S-nitrosoglutathione reductase

Inventors: Xicheng Sun (Broomfield, CO); Jian Qiu (Longmont, CO); Jan Wasley (Guilford, CT)
Assignee: N30 Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,481,590
App. No.
13/521,820
Granted
Jul 9, 2013
Kind
B2
Abstract

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Claims (31)

1. The compound of formula (I)

wherein

R 1 is selected from the group consisting of CF 3 , CF 2 H, CF 2 CH 3 , CF 2 CH 2 CH 3 , methyl, isopropyl, isobutyl, cyclopentyl, CH 2 OCH 3 , SCH 3 , benzyl, thiophen-2-yl, and thiophen-3-yl;

R 2 is selected from H, F, Cl, methoxy, and cyano; and

R 3 is selected from H, F, Cl, and methoxy.

2. The compound of claim 1 wherein R 1 is selected from the group consisting of CF 3 , CF 2 H, and CF 2 CH 3 ; and R 2 is hydrogen.

3. The compound of claim 1 wherein R 1 is selected from the group consisting of CF 3 , methyl, isopropyl, and isobutyl; and R 2 and R 3 are both hydrogen.

4. The compound of claim 1 wherein R 1 is selected from the group consisting of CF 3 , methyl, isopropyl, isobutyl, CF 2 H, CF 2 CH 3 , and CF 2 CH 2 CH 3 ; and R 2 and R 3 are both hydrogen.

5. The compound of claim 1 selected from the group consisting of

4-(2-(difluoromethyl)-7-hydroxy-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(7-hydroxy-2-(methoxymethyl)-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(7-hydroxy-2-isopropyl-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(2-cyclopentyl-7-hydroxy-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(7-hydroxy-2-methyl-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(2-benzyl-7-hydroxy-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(7-hydroxy-4-oxo-2-(thiophen-2-yl)-4H-chromen-3-yl)benzoic acid;

4-(7-hydroxy-4-oxo-2-(thiophen-3-yl)-4H-chromen-3- yl)benzoic acid;

4-(7-hydroxy-2-isobutyl-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoic acid;

4-(7-hydroxy-2-(methylthio)-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(6-chloro-7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoic acid;

4-(6-fluoro-7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoic acid;

2-fluoro-4-(7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoic acid;

3-chloro-4-(7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoic acid;

4-(2-(1,1-difluoroethyl)-7-hydroxy-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(7-hydroxy-6-methoxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoic acid;

2-chloro-4-(7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoic acid;

4-(2-(1,1-difluoropropyl)-7-hydroxy-4-oxo-4H-chromen-3-yl)benzoic acid;

4-(7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)-3-methoxybenzoic acid; and

4-(6-cyano-7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoic acid.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of the previous claims together with a pharmaceutically accepted carrier or excipient.

Assignments (3)
CHANGE OF NAME Recorded Mar 4, 2015
From: N30 PHARMACEUTICALS, INC.
To: NIVALIS THERAPEUTICS, INC.
Reel/Frame 035125/0164 →
CONVERSION OF N30 PHARMACEUTICALS, LLC FROM A DELAWARE LIMITED LIABILITY COMPANY TO A DELAWARE CORPORATION UNDER THE NAME OF N30 PHARMACEUTICALS, INC. Recorded Aug 10, 2012
From: N30 PHARMACEUTICALS, LLC
To: N30 PHARMACEUTICALS, INC.
Reel/Frame 028769/0496 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2012
From: SUN, XICHENG; QIU, JIAN; WASLEY, JAN
To: N30 PHARMACEUTICALS, LLC
Reel/Frame 028536/0959 →
Continuity (1)
Related Publication 20120295966A1 · Nov 22, 2012